What Ocrevus treats.
- Relapsing forms of multiple sclerosis (RRMS, SPMS, CIS)
- Primary progressive multiple sclerosis (PPMS)
The mechanism.
Ocrevus (ocrelizumab) selectively targets and depletes CD20-positive B cells, which play a key role in multiple sclerosis pathology. By reducing these immune cells, Ocrevus has been shown to significantly slow disease progression and reduce relapse rates compared to standard interferon therapy.
Your Ocrevus infusion experience.
Your first Ocrevus dose is split into two infusions of 300 mg given two weeks apart, each lasting about 2.5 hours. After that, maintenance is a single 600 mg infusion every 6 months, lasting about 3.5 hours (or 2 hours with the shorter infusion protocol). Pre-medications are required to reduce infusion reactions.
Insurance & out-of-pocket cost.
Ocrevus is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.